CGEM 8-K: SEC filing

Cullinan Therapeutics

Filed with the SEC on Nov 9, 2026 · accession 0001193125-26-452644

CGEM filed a 8-K (current report) with the SEC on Nov 9, 2026. Cullinan Therapeutics announced positive interim Phase 1b/2a clinical data for velinotamig in patients with active, refractory, moderate-to-severe systemic lupus erythematosus (SLE), showing a favorable safety profile and clinical activity across disease activity, serologic markers, and renal…

Summary of the filing

Cullinan Therapeutics announced positive interim Phase 1b/2a clinical data for velinotamig in patients with active, refractory, moderate-to-severe systemic lupus erythematosus (SLE), showing a favorable safety profile and clinical activity across disease activity, serologic markers, and renal function measures.

For details, click here →How to read a 8-K →

Key details

Registrant, holds global ex-greater china exclusive license to develop velinotamigCullinan Therapeutics, Inc.

Licensor and trial sponsor conducting the phase 1b/2a trial in chinaChongqing Genrix Biopharmaceutical Co., Ltd.

✦ Ask GOAX AI about this filing — what it means for CGEM, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for CGEM?

Click here

Frequently asked questions

What did CGEM file with the SEC on Nov 9, 2026?

CGEM filed a 8-K (SEC filing). Cullinan Therapeutics announced positive interim Phase 1b/2a clinical data for velinotamig in patients with active, refractory, moderate-to-severe systemic lupus erythematosus (SLE), showing a favorable safety profile and clinical activity across disease activity, serologic markers, and renal function measures.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other CGEM SEC filings

Get alerts when CGEM files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

CGEM overview CGEM analysis CGEM news Latest SEC filings